Senocohort: Identification of Predictive Biomarkers in Breast Cancer Treatment

Breast cancer is a heterogeneous disease with multiple molecular subtypes, each requiring tailored therapeutic strategies. The recent introduction of targeted therapies, immunotherapies, and antibody-drug conjugates has expanded treatment options, yet their efficacy varies depending on tumor subtype. This non-interventional study aims to identify novel predictive biomarkers of response or resistance to these emerging therapies. The Senocohort study will prospectively collect clinical, biological, imaging, and organoid-derived data from breast cancer patients, with a focus on hormone receptor-negative tumors. The ultimate goal is to improve precision medicine strategies and patient stratification

Not yet recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Breast Cancer Breast Cancer (Triple Negative Type) Breast Diseases Breast Neoplasms Neoplasms Neoplasms by Site Skin Diseases Skin and Connective Tissue Diseases Triple Negative Breast Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

About this study

Senocohort is a prospective, bicentric cohort study designed to collect clinico-biological data and establish a biobank of patient-derived tumor organoids (PDOs) from residual tissue samples obtained during routine care. The aim is to identify new multimodal biomarkers (molecular, cellular, and imaging) predictive of response or resistance to breast cancer therapies, with evaluation based on progression-free survival. The study targets an enriched population of hormone receptor-negative breast cancers, particularly triple-negative subtypes, which currently lack effective targeted treatments. Samples will be used for genomic analyses, PDO development, and circulating biomarker studies, with 10 years of clinical follow-up.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age ≥ 18 years
Histologically confirmed breast cancer
Managed at Saint-Louis Hospital
No opposition to participation in research
Affiliation to the French national health system

Exclusion criteria

Expressed opposition to research
Legal incapacity or under legal protection
Patients under State Medical Aid (AME)

Treatment and study plan

Patients follow-up

Other

Blood sampling, residual tissue material collection and clinical data collection

Primary outcomes

Number of Predictive Multimodal Biomarkers identified

Time frame: Up to 10 years

Discovery and validation of molecular, cellular, and imaging biomarkers associated with response or resistance to therapies, evaluated on progression-free survival.

Secondary outcomes

Overall Survival Analysis by Biomarker Subgroup

Time frame: Up to 10 years

Evaluation of overall survival based on biomarker-defined subgroups.
Multimodal biomarker performance

Time frame: Up to 10 years

Assessment of the added value of combining multiple types of biomarkers (e.g., genomic + imaging).
Drug Sensitivity in PDO Models

Time frame: Up to 10 years

Ex vivo response of PDOs to approved or experimental therapies, correlated with clinical outcomes.

Study contacts

Contact information is provided by the study sponsor or research team.

Jérôme Lambert, MD PhD

CONTACT

[email protected]

0142499742 ext. +33

Luis Texeira, MD PhD

CONTACT

[email protected]

01 42 49 96 13 ext. +33

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Registry information

Official study title

Recherche de Biomarqueurs prédictifs de réponse ou de résistance Dans Les Traitements Des Cancers du Sein

Acronym: SENOCOHORT

Important dates

Study start: 2026
Primary completion: 2031
Study completion: 2041
First posted: Sep 22, 2026
Registry last updated: Sep 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not yet recruiting